Anoat Therapeutics is a technology company.
Anoat Therapeutics has raised $2.0M across 1 funding round.
Anoat Therapeutics has raised $2.0M in total across 1 funding round.
Anoat Therapeutics has raised $2.0M in total across 1 funding round.
Anoat Therapeutics's investors include Advent Life Sciences.
Anoat Therapeutics is a preclinical-stage biotechnology company based in Paris, France, specializing in developing novel, mutation-agnostic therapies for cystic fibrosis (CF) patients with high unmet medical needs, particularly those ineligible for or unresponsive to existing CFTR modulator therapies.[1][2][4] The company targets rare diseases like CF—a progressive genetic condition affecting the lungs, pancreas, and other organs in about 105,000 people across 94 countries—by advancing an innovative, disease-modifying approach through in vivo and in vitro pharmacology assessments to select lead candidates.[2][3] In 2024, Anoat raised €2 million ($2.17 million) in seed funding from AdBio Partners to fuel these efforts, marking early growth momentum in a space with limited treatment options.[1][2][5]
Anoat Therapeutics emerged as a French biotech focused on CF, though specific founding year and founders are not detailed in available sources; it operates in the preclinical phase with leadership from CEO Vincent Bischoff, a seasoned biotech professional emphasizing a team of exceptional scientists, drug development experts, and physician networks.[2] The idea stems from promising proof-of-concept data addressing gaps in CF treatments, supported by collaborations with patient associations to meet needs of underserved patients.[2] A pivotal early moment was the €2M seed funding in 2024 from AdBio Partners, enabling lead candidate selection and program advancement for genetic diseases including CF.[1][2][5]
Anoat rides the trend of precision medicine for rare genetic diseases, particularly CF, where market forces favor mutation-agnostic solutions amid ~105,000 global patients and gaps in CFTR therapies.[2] Timing aligns with rising investments in lung-targeted gene therapies, as seen in parallel funding like the Cystic Fibrosis Foundation's up to $2M for Nanite Inc., highlighting ecosystem momentum for innovative delivery tech.[2] Anoat influences the biopharma landscape by filling voids for non-responsive CF patients, potentially expanding to other genetic diseases and boosting France's biotech hub in Paris.[1][4]
Anoat's next steps center on advancing preclinical programs—selecting a lead CF candidate post-€2M funding and initiating series A for genetic disease expansion, amid trends like gene delivery advancements and rare disease incentives.[2] Evolving regulatory support and investor interest in mutation-agnostic therapies could amplify its role, potentially delivering first-in-class options that transform underserved CF lives. This positions Anoat as an early innovator bridging unmet needs in rare disease biotech.
Anoat Therapeutics has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in June 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 1, 2023 | $2.0M Seed | Advent Life Sciences |